Become A Featured Company

The State of Illinois Teams Up with Helix TCS to Take on the Opioid Epidemic

Ryan Allway

February 27th, 2019

Exclusive, Top News

The opioid epidemic has become a major health risk for the United States and Canada. After years of overprescribing, opioid addiction affects a record number of individuals that are increasingly turning to dangerous synthetic opioids. These trends have led to a growing number of overdose deaths across North America. The good news is that medical cannabis has helped turn the tide in a growing number of states.

Helix TCS Inc. (OTCQB: HLIX), through its subsidiary BioTrackTHC, recently teamed up with the State of Illinois to measure the impact of medical cannabis on opioid use in its Opioid Alternative Pilot Program. The program could become a model for other states facing the same problems, while opening the door for more revenue opportunities for Helix TCS’ unique software solutions.

Click here to receive an investor deck and corporate updates

Growing Opioid Epidemic

Drug overdoses have become the leading cause of death of Americans under 50—and two-thirds of those deaths come from opioids. As the most prescribed class of drugs in the U.S., long-term opioid use has skyrocketed over the past several years. Painkiller prescriptions tripled from 76 million to 219 million per year between 1991 and 2011, and nowadays, nearly 300 million prescriptions are issued each year.

There are many ways that regulators aim to fight the opioid epidemic. For example, methadone clinics offer long-term treatment options for addicts while behavioral treatments are designed to help people kick their addiction. The problem is that these solutions don’t address the underlying problem of nearly one-third of Americans living with chronic pain—chronic pain that needs some form of treatment.

The legalization of medical cannabis across a growing number of states could offer a solution. According to the American Medical Association, states with modernized cannabis laws see a significant reduction in opioid dependence and opioid-related deaths. The assumption is that many chronic pain sufferers are amenable to using cannabinoids as an alternative treatment, and cannabinoids don’t have the same adverse side-effects.

Click here to receive an investor deck and corporate updates

BioTrackTHC Powers Research

The State of Illinois has become a pioneer in measuring these trends with its Opioid Alternative Pilot Program. By tracking patients taking alternative medications, such as medical cannabis, the state hopes to find clear pathways to fight the nationwide epidemic. The challenge is tracking the use of medical cannabis since it occurs outside of the traditional medical system where doctors issue prescriptions purchased at pharmacies.

Helix TCS Inc.’s (OTCQB: HLIX) BioTrackTHC subsidiary provides the key missing ingredient—a software application that tracks medical cannabis across the supply chain. Earlier this month, the company announced that the State of Illinois selected its software to track medical cannabis sales for patients participating in the Opioid Alternative Pilot Program, in addition to its existing tracking and tracing of the state’s medical cannabis supply chain.

“Helix TCS is uniquely positioned to deliver the critical tracking and compliance technology infrastructure surrounding both forms of medicine in existing and emerging medical and recreational cannabis markets through our subsidiary, BioTrackTHC, and will be able to leverage tracking data to directly correlate changes in opioid use to medical cannabis expansion,” says Helix TCS Executive Chairman and CEO, Zachary L. Venegas.

The agreement in Illinois could become a template for other states looking to implement similar programs, with key states, including New York, considering this path and also utilizing the BioTrackTHC solution for government oversight of the state’s medical cannabis program. With its significant footprint in the supply chain portion of the market, the technology is a natural solution for expansion into the research space. In fact, the company was originally formed to track the dispensing of prescription painkillers in South Florida before pivoting to the licensed cannabis industry in 2010.

Click here to receive an investor deck and corporate updates

Looking Ahead

Helix TCS Inc. (OTCQB: HLIX) is a leading provider of ancillary services to the legal cannabis industry, helping owners and operators of licensed businesses remain competitive, compliant, and secure. The company’s products already reach over 2,000 customers across 33 states in five countries, and its software has processed over $18 billion in cannabis sales since 2010. Investors may want to take a closer look at the company given these dynamics.

For more information, visit the company’s website at www.helixtcs.com.

Disclaimer  

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading